Evidence summaries, dosing frameworks, and product quality standards to support informed conversations with your patients about CBD supplementation.
A summary of published findings on CBD for common conditions. Research is ongoing; findings below reflect preliminary and emerging evidence.
Research published in JAMA and Pain suggests CBD may support pain modulation through the endocannabinoid system (ECS). Preliminary evidence indicates CBD may reduce inflammatory cytokines via CB2 receptor activity. Studies suggest potential benefit in neuropathic and musculoskeletal pain management as a complementary option.
Preliminary research suggests CBD may support sleep quality by reducing anxiety-related sleep disturbance and modulating cortisol rhythms. A 2019 study in The Permanente Journal found that 66% of patients reported improved sleep scores within the first month of CBD use. Research on direct sleep architecture effects is ongoing.
Studies published in Neuropsychopharmacology and Frontiers in Immunology indicate CBD may modulate serotonin 5-HT1A receptor activity and reduce cortisol response to stress. Preliminary evidence suggests anxiolytic effects at doses of 300–600mg in acute settings; typical supplemental doses are substantially lower.
Animal and in vitro studies suggest CBD may suppress pro-inflammatory pathways including NF-κB and TNF-α signaling. Clinical human data on chronic systemic inflammation is limited but emerging. Physicians should note this area shows promise but requires more rigorous human trial data before clinical application.
The ECS regulates pain, mood, inflammation, and sleep via CB1 (central) and CB2 (peripheral/immune) receptors. CBD modulates ECS activity without direct receptor binding — unlike THC. It also interacts with TRPV1 (pain), 5-HT1A (mood/anxiety), and GPR55 receptors, suggesting a multi-target mechanism relevant across several conditions.
Hemp-derived CBD (≤0.3% THC) is federally legal under the 2018 Farm Bill and legal in Ohio. It is classified as a dietary supplement, not a scheduled substance. Physicians may discuss CBD as a complementary supplement option. The FDA has approved one CBD-based drug (Epidiolex) for seizure disorders — this is distinct from OTC dietary supplement CBD.
A reference framework based on published research and clinical practice patterns. This is not prescriptive — consult product-specific documentation for exact protocols.
| Tier | Daily Dose Range | Common Use Context | Notes |
|---|---|---|---|
| Low Dose | 5–15 mg/day | General wellness, mild stress, sleep support for sensitive patients | Recommended starting point. Allow 1–2 weeks at this dose before titrating. Suitable for patients with low body weight or high sensitivity. |
| Standard Dose | 15–50 mg/day | Moderate pain, anxiety, inflammation support, sleep maintenance | Most clinical research uses doses in this range. Can be split into twice-daily dosing (morning + evening) for sustained effect. |
| High Dose | 50–100 mg/day | Chronic neuropathic pain, significant inflammation, post-surgical recovery support | Some research protocols use doses in this range. Monitor for drug interactions (particularly CYP3A4/CYP2C19 substrate medications). Titrate gradually. |
| Research Doses | 100–600 mg/day | Clinical trial contexts (anxiety, psychosis research) | Generally not applicable to OTC dietary supplement use. Referenced for clinical context only. Consult literature directly for specific conditions. |
Sublingual / tincture: 15–45 min onset, 4–6 hr duration.
Softgels / capsules: 30–90 min onset, 6–8 hr duration.
Topicals: 15–30 min local onset, localized effect only.
CBD inhibits CYP3A4 and CYP2C19 enzymes at higher doses. Physicians should exercise caution with patients on:
• Warfarin (INR monitoring advised)
• Clobazam and other benzodiazepines
• Valproate
• Other CYP3A4/2C19 substrate medications
Research suggests CBD bioavailability increases significantly when taken with a fatty meal (up to 5x vs. fasted state). Advise patients to take CBD with food containing healthy fats for consistent absorption and effect.
Not all CBD products are equal. Here's what to look for when evaluating any CBD brand for your patients — and what CBD Health Collection delivers on every product.
Every batch tested by an independent, ISO-accredited lab. Confirms potency (CBD mg matches label) and absence of contaminants. COAs should be batch-specific and publicly accessible.
Current Good Manufacturing Practices certification ensures pharmaceutical-grade consistency. CBD Health Collection manufactures in an FDA-registered, cGMP-compliant facility — the same standard applied to OTC pharmaceuticals.
Federally compliant hemp-derived CBD must contain ≤0.3% delta-9 THC by dry weight. All products should have THC levels confirmed by third-party lab testing on the COA — not just stated on the label.
Hemp is a bioaccumulator — it absorbs soil contaminants. Lead, arsenic, mercury, and cadmium must be tested to confirm levels below safety thresholds. This is non-negotiable for physician-recommended products.
Full panel pesticide screening and residual solvent testing (from extraction processes) should be included in COAs. Absence of these tests is a disqualifying red flag for clinical recommendation.
Labels should state CBD mg per serving (not just per bottle), list all ingredients, include a supplement facts panel, and carry no unapproved health claims. Opaque labeling is a compliance risk.
Answers to the questions physicians most commonly ask before evaluating CBD supplementation for their patients.